Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 9/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | USP1 | O94782 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18256610 | 0.93 | PIK3CA (0.43) | PARGPIK3CAPRKDC | |
| SCHEMBL18256611 | 0.91 | PARG (0.46) | PARGPIK3CAERCC5FEN1PRKDC | |
| SCHEMBL18256587 | 0.85 | MTOR (0.44) | PARGPIK3CAPRKDC | |
| SCHEMBL18256612 | 0.84 | PIK3CA (0.43) | PARGPIK3CAPRKDC | |
| SCHEMBL18256588 | 0.80 | PARG (0.41) | PARGPIK3CA | |
| SCHEMBL18256616 | 0.78 | PIK3CA (0.43) | PARGPIK3CA | |
| SCHEMBL18256629 | 0.78 | FEN1 (0.49) | PARGPIK3CAFEN1 | |
| SCHEMBL18256614 | 0.77 | PARG (0.43) | PARGPIK3CAERCC5FEN1PRKDC | |
| SCHEMBL18256631 | 0.76 | BRD4 (0.43) | PIK3CANAMPT | |
| SCHEMBL18256684 | 0.76 | MTOR (0.44) | PARGPIK3CAPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| WO-2016184313-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | 南京明德新药研发股份有限公司 | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | PARG 1778/4885PIK3CA 1359/4885ERCC5 1254/4885 |
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | PARG 1778/4885PIK3CA 1359/4885ERCC5 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.